Search clinical trials for: angiotensin II

Total 32036 results

The George Institute
The University of New South Wales

Recruiting

Triple Therapy Prevention of Recurrent Intracerebral Disease EveNts Trial (TRIDENT)

Hypertension | Intracerebral Haemorrhage (ICH)

United Kingdom, Australia, Singapore, Georgia, Netherlands, Nigeria, Sri Lanka, Switzerland, Brazil, Malaysia, Taiwan, Vietnam
Vanderbilt University

Recruiting

Metabolic Effects of Angiotensin-(1-7)

Hypertension | Obesity | Insulin Resistance | Metabolic Cardiovascular Syndrome

United States
EMS

Not yet recruiting

Efficacy and Safety of Olmesartan Associated With Chlorthalidone in Essential Arterial Hypertension Control

Essential Arterial Hypertension
EMS

Not yet recruiting

Efficacy and Safety of Olmesartan Associated With Chlorthalidone Versus Benicar HCT® in Essential Hypertension Control

Arterial Hypertension
University of Alberta

Recruiting

The Intracerebral Hemorrhage Acutely Decreasing Arterial Pressure Trial II (ICH-ADAPT II)

Intracerebral Hemorrhage

Canada
MD, PhD, Annemarie Lyng Svensson

Recruiting

Early Rheumatoid Arthritis COR Intervention (ERACORI)

Cardiovascular Diseases | Rheumatoid Arthritis

Denmark
Sunnybrook Health Sciences Centre
Alzheimer's Drug Discovery Foundation; Weston Brain Institute

Recruiting

Telmisartan vs. Perindopril in Mild-Moderate Alzheimer's Disease Patients (SARTAN-AD)

Alzheimer's Disease

Canada
Teva takeda

Active, not recruiting

A Study of Azilsartan in Children From 6 to Less Than 16 Years Old With High Blood Pressure

Hypertension

Japan
Emory University
National Institute on Aging (NIA)

Completed

Health Evaluation in African Americans Using RAS Therapy (HEART)

Alzheimer's Disease

United States
Organon and Co

Completed

An Extension Study Designed to Assess Effects of Losartan on Proteinuria in Pediatric Populations (MK-0954-326 AM1,EXT1(AM2))

Proteinuria
Organon and Co

Terminated

A Study of Losartan Compared to Losartan/HCTZ in Pediatric Patients With Hypertension (0954A-327)

Hypertension
Organon and Co

Completed

A Study of Safety and Efficacy in MK-0954A Combination in Participants With Hypertension (MK-0954A-373 AM3)

Hypertension
Organon and Co

Completed

Efficacy of Losartan + Amlodipine Compared to Amlodipine Alone in the Treatment of Uncontrolled High Blood Pressure (MK-0954F-399)

Hypertension
Organon and Co

Completed

LAAS (Losartan Anti-Atherosclerosis Study)(0954-330)(COMPLETED)

Hypertension
Organon and Co

Completed

A Long-term Study of the Safety of MK-0954A in Patients With Essential Hypertension (MK-0954A-351)

Hypertension
Organon and Co

Completed

MK-0954A in Japanese Patients With Essential Hypertension Not Adequately Controlled With Losartan (MK-0954A-352)

Hypertension
Organon and Co

Completed

Study of Losartan in Pediatric Patients With Hypertension (MK-0954-337)

Hypertension
Organon and Co

Completed

Study to Evaluate Potential Decrease in Hospitalization Events, Time Between Events, and Increasing Longevity in Patients With Symptomatic Heart Failure (0954-948)

Heart Failure
Organon and Co

Completed

BP-EASE -Effectiveness of Losartan 50 mg/Hydrochlorothiazide (HCTZ) 12.5 mg Versus Valsartan 80 mg/HCTZ 12.5 mg Titrated as Needed in Patients With Essential Hypertension Not Controlled on Monotherapy (0954A-333) (EASE)

Hypertension
Organon and Co

Completed

SAALT: Subtracting Salt and Adding Losartan Trial (0954A-335)

Hypertension
Organon and Co

Completed

A 52 Week Study to Evaluate the Effects of Losartan With or Without HCTZ on Plasma Glucose, Metabolic Parameters, Blood Pressure in Hypertensive Patients With Metabolic Syndrome (0954A-331)

Hypertension | Metabolic Disorder
Alnylam Pharmaceuticals

Active, not recruiting

Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (KARDIA-2)

Hypertension

United States, Canada, Latvia, Poland, United Kingdom, Germany, Lithuania, Estonia, Puerto Rico
University of Alabama at Birmingham
University of Colorado, Denver; Translational Research Institute for Metabolism...

Active, not recruiting

ACES - ACE Inhibitors Combined With Exercise for Seniors With Hypertension (ACES)

Hypertension | Sedentary Lifestyle | Aging

United States
University of Florida
National Institute on Aging (NIA); Abbott

Completed

The ENRGISE (ENabling Reduction of Low-Grade Inflammation in SEniors) Pilot Study (ENRGISE)

Inflammation

United States
Shanghai Pharmaceuticals Holding Co., Ltd

Completed

Study to Evaluate the Efficacy and Safety of SPH3127 In Patients With Mild-moderate Essential Hypertension

Essential Hypertension

China
Milton S. Hershey Medical Center

Terminated

Angiotensin-(1-7) in Peripheral Arterial Disease

Peripheral Arterial Disease

United States
James J. Irrgang
Brooke Army Medical Center; Wake Forest University

Terminated

Phase 1/2 Prospective Double-Blind Placebo-Controlled Randomized Clinical Trial of Losartan to Treat Grade II & III Hamstring Strains

Hamstring Injury

United States
Oslo University Hospital
University of Oslo

Completed

Effects of Valsartan vs Amlodipine and Low BP on Kidney Outcomes in Essential Hypertension (VALUE)

Essential Hypertension
Hackensack Meridian Health

Terminated

Study of TelmisartanFor the Prevention of Acute GVHD Post Allogeneic Hematopoietic Stem Cell Transplantation

GVHD

United States
Travere Therapeutics, Inc.

Active, not recruiting

Study of Sparsentan in Patients With Primary Focal Segmental Glomerulosclerosis (FSGS) (DUPLEX)

Focal Segmental Glomerulosclerosis

United States, Australia, Belgium, Croatia, Estonia, Germany, Hong Kong, Italy, Korea, Republic of, Poland, Portugal, Spain, Taiwan, United Kingdom, Argentina, Brazil, Canada, Czechia, Denmark, France, New Zealand, Sweden
Travere Therapeutics, Inc.

Completed

Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis (DUET)

Focal Segmental Glomerulosclerosis

United States, Italy, Czechia
George Medicines PTY Limited

Completed

Efficacy and Safety of GMRx2 Compared to Dual Combinations for the Treatment of Hypertension (GMRx2_ACT)

Hypertension

Australia, United States, United Kingdom, Poland, Sri Lanka, New Zealand, Czechia
Mylan Pharmaceuticals Inc

Completed

Fasting Study of Olmesartan Medoxomil Tablets 40 mg and Benicar® Tablets 40 mg

Healthy

United States
Mylan Pharmaceuticals Inc

Completed

Fed Study of Olmesartan Medoxomil and Hydrochlorothiazide Tablets 40 mg/25 mg and Benicar HCT® Tablets 40 mg/25 mg

Healthy

United States
Mylan Pharmaceuticals Inc

Completed

Fasting Study of Olmesartan Medoxomil and Hydrochlorothiazide Tablets 40 mg/25 mg and Benicar HCT® Tablets 40 mg/25 mg

Healthy

United States
Mylan Pharmaceuticals Inc

Completed

Fed Study of Olmesartan Medoxomil Tablets 40 mg and Benicar® Tablets 40 mg

Healthy

United States
University of Florida
United States Department of Defense

Active, not recruiting

Women's IschemiA TRial to Reduce Events In Non-ObstRuctive CAD (WARRIOR)

Coronary Artery Disease

United States, Puerto Rico
Steadman Philippon Research Institute
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

Active, not recruiting

Use of Senolytic and Anti-Fibrotic Agents to Improve the Beneficial Effect of Bone Marrow Stem Cells for Osteoarthritis

Osteoarthritis, Knee

United States
George Washington University

Completed

Intravenous AII for the Treatment of Severe Hypotension in High Output Shock: A Pilot Study (ATHOS)

Septic Shock

United States
Novartis Pharmaceuticals

Completed

CLCZ696B2319E1 OL Extension Study to Evaluate Long-term Safety of Sacubitril/Valsartan in Pediatric Patients With HF

Heart Failure

United States, Italy, Croatia, India, Japan, Poland, Spain, Taiwan, Austria, Korea, Republic of, Germany, Lebanon, Thailand, Canada, Bulgaria, Russian Federation, Turkey, Switzerland, Argentina, Hungary, Portugal, Finland, South Africa and more
Pachankis, Yang I., M.D.
First Affiliated Hospital of Chongqing Medical University

Completed

Detoxification From the Lipid Tract

COVID-19 Vaccine Adverse Reaction

China
Horng Chen

Enrolling by invitation

Enhancing the Natriuretic Peptide System in HFpEF

Chronic Kidney Diseases | Heart Failure With Preserved Ejection Fraction

United States
Laboratorios Silanes S.A. de C.V.

Completed

Efficacy and Safety of Losartan/Chlorthalidone vs Losartan/Hydrochlorothiazide in Essential Arterial Hypertension

Essential Arterial Hypertension

Mexico
St. Olavs Hospital
Ullevaal University Hospital; University Hospital of North Norway; Norwegian... and other collaborators

Active, not recruiting

Candesartan for Migraine Prevention: (CandMig-3)

Migraine

Norway, Estonia
Qianfoshan Hospital

Active, not recruiting

Therapeutic Drug Use for CKD Patients

Chronic Kidney Disease

China
University of Alabama at Birmingham
National Heart, Lung, and Blood Institute (NHLBI)

Terminated

Preventing Sickle Cell Kidney Disease

Hypertension | Proteinuria | Sickle Cell Disease | Anemia, Sickle Cell | Kidney Disease

United States
Methodist Health System

Enrolling by invitation

Efficacy and Safety of Sacubitril/Valsartan in African American Patients With Heart Failure With Reduced Ejection Fraction

Heart Failure

United States
University of Zagreb

Active, not recruiting

Sacubitril/Valsartan in Left Ventricular Assist Device Recipients (ENVAD-HF)

Heart Failure

Netherlands, Croatia, Poland, Czechia
Massachusetts General Hospital
National Cancer Institute (NCI)

Active, not recruiting

Hearing Outcomes Using Fractionated Proton Radiation Therapy for Vestibular Schwannoma

Vestibular Schwannoma | Acoustic Neuroma

United States
Novartis Pharmaceuticals

Active, not recruiting

A Safety Study of Sacubitril/Valsartan in Japanese Pediatric Patients With Heart Failure Due to Systemic Left Ventricle Systolic Dysfunction Who Have Completed CLCZ696B2319E1 Study

Heart Failure

Japan

Search clinical trials for: angiotensin II

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ethiopia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations